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Mesenchymal stem cells (MSCs), due to their potential for differentiation into alveolar epithelial cells and their immunosuppressive
characteristics, are considered a new therapeutic agent in cell-based therapy of inflammatory lung disorders, including chronic
obstructive pulmonary disease (COPD). Since most of the MSC-mediated beneficent effects were the consequence of their
paracrine action, herewith, we investigated the effects of a newly designed MSC-derived product “Exosome-derived Multiple
Allogeneic Protein Paracrine Signaling (Exo-d-MAPPS)” in the attenuation of chronic airway inflammation by using an animal
model of COPD (induced by chronic exposure to cigarette smoke (CS)) and clinical data obtained from Exo-d-MAPPS-treated
COPD patients. Exo-d-MAPPS contains a high concentration of immunomodulatory factors which are capable of attenuating
chronic airway inflammation, including soluble TNF receptors I and II, IL-1 receptor antagonist, and soluble receptor for
advanced glycation end products. Accordingly, Exo-d-MAPPS significantly improved respiratory function, downregulated
serum levels of inflammatory cytokines (TNF-α, IL-1β, IL-12, and IFN-γ), increased serum concentration of
immunosuppressive IL-10, and attenuated chronic airway inflammation in CS-exposed mice. The cellular makeup of the
lungs revealed that Exo-d-MAPPS treatment attenuated the production of inflammatory cytokines in lung-infiltrated
macrophages, neutrophils, and natural killer and natural killer T cells and alleviated the antigen-presenting properties of
lung-infiltrated macrophages and dendritic cells (DCs). Additionally, Exo-d-MAPPS promoted the expansion of
immunosuppressive IL-10-producing alternatively activated macrophages, regulatory DCs, and CD4+FoxP3+T regulatory cells
in inflamed lungs which resulted in the attenuation of chronic airway inflammation. In a similar manner, as it was observed
in an animal model, Exo-d-MAPPS treatment significantly improved the pulmonary status and quality of life of COPD
patients. Importantly, Exo-d-MAPPS was well tolerated since none of the 30 COPD patients reported any adverse effects
after Exo-d-MAPPS administration. In summing up, we believe that Exo-d-MAPPS could be considered a potentially new
therapeutic agent in the treatment of chronic inflammatory lung diseases whose efficacy should be further explored in large
clinical trials.
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1. Introduction
COPD is a common, progressive, inflammatory disease
characterized by persistent and not fully reversible airflow
limitation associated with an abnormal and deregulated
chronic inflammatory response to noxious particles or gases
[1–3]. Hallmarks of early stages of COPD include remodeling
of small airways induced by persistently activated innate
immune cells (alveolar macrophages, neutrophils, natural
killer (NK), and DCs), while severe stages of COPD are char-
acterized by the development of lung lymphoid follicles due
to the enhanced activation of CD8+ cytotoxic T lymphocytes
(CTLs) and CD4+ T helper cells and their crosstalk with B
cells [4–8]. Continuous activation of resident and lung-
infiltrated immune cells results in structural and functional
changes in the inflamed lungs, including the narrowing of
small airways, mucus hyperproduction, cilia dysfunction,
and destruction of the lung parenchyma [9]. Accordingly,
COPD is manifested by persistent and progressive breath-
lessness (usually worse during physical activities), chronic
cough, regular production of sputum (in three or more
months during two consecutive years), wheeze, and chest
tightness (as signs of severe COPD) [9].
In a similar manner, as it is observed in human pathol-
ogy, cigarette smoke (CS) exposure results in the develop-
ment of COPD in mice [10]. Therefore, mouse models are
usually used to elucidate molecular and cellular mechanisms
involved in the development and progression of human
COPD [10]. Importantly, there are strain-dependent differ-
ences in susceptibility to COPD-related injury between
BALB/c and C57BL/6 mice. BALB/c mice were more sensi-
tive than C57BL/6 mice to COPD-related emphysema, one
of the major components of CS-induced COPD [11]. Signif-
icantly higher mortality, greater body weight loss, greater
decline in lung function, and a greater loss of alveolar tissue
were noticed in BALB/c mice compared to C57BL/6 mice
[11]. Importantly, immune cells that play a crucially
important pathogenic role in the development of cigarette
smoke-induced COPD (TNF-α-producing, classically acti-
vated (M1) macrophages and neutrophils, as well as IL-17-
producing lymphocytes) were found in significantly higher
numbers in the injured lungs of BALB/c mice compared to
C57BL/6 mice, indicating the advantage of using BALB/c
mice in COPD-related animal studies [10–12].
Available medicaments (anti-inflammatory drugs, β2-
agonists, and anticholinergics) efficiently reduce airflow lim-
itation and improve the quality of life of COPD patients, but
they are not able to prevent disease progression andmortality
[13]. Since COPD is projected to become the third leading
cause of disease mortality worldwide by 2020 [1, 2], new ther-
apeutic approaches are urgently needed in order to prevent
progression and exacerbation of COPD.
MSCs are self-renewable, multipotent cells which are able
to differentiate into alveolar epithelial cells and are able to
modulate the proliferation, activation, and effector function
of all immune cells that play an important role in the
development, progression, and exacerbation of COPD [14].
Accordingly, several experimental studies demonstrated
the beneficial effects of MSCs in the treatment of COPD
[15–18]. Intravenously, intratracheally, and intrabronchi-
ally injected MSCs managed to significantly attenuate
emphysematous changes and notably improve pulmonary
function in animal models of COPD [19]. The beneficial
effects of MSCs were mainly attributed to the activity of
MSC-derived products (conditioned medium (MSC-CM)
and exosomes (MSC-Exos)): nanosized extracellular vesicles
that, in a paracrine and endocrine manner, delivered proteins,
lipids, DNA fragments, and mRNA to the immune, endothe-
lial, and alveolar epithelial cells modulating their function
[20]. Several lines of evidence suggested that MSCs derived
from placental tissues (PL-MSCs) had superior biological
properties compared to MSCs derived from adult tissues
[21–24]. In line with these findings, we recently developed
the “Exosome-derived Multiple Allogeneic Protein Paracrine
Signaling (Exo-d-MAPPS),” a PL-MSC-derived product
whose activity is based on exosomes, growth factors, and
immunomodulatory cytokines capable of attenuating inflam-
mation and promoting the regeneration of injured tissues
[25]. Herewith, we described the molecular and cellular mech-
anisms which were responsible for the Exo-d-MAPPS-based
attenuation of airway inflammation in BALB/c mice and in
patients suffering from COPD.
2. Material and Methods
2.1. Exo-d-MAPPS Sample Acquisition. Sterile Exo-d-MAPPS
is an engineered biological product obtained from PL-MSCs
previously collected from healthy human donors. PL-MSC
samples were obtained with patient consent as well as institu-
tional ethical approval and kept at 4°C until processed. All
donors prior to or at the time of collection were tested by lab-
oratories certified under the Clinical Laboratory Improve-
ment Amendments (CLIA) and were found negative using
United States (US) Food and Drug Administration (FDA)
licensed tests for the detection of at minimum, hepatitis B
virus, hepatitis C virus, human immunodeficiency virus types
1/2, and Treponema pallidum.
The Exo-d-MAPPS samples used in this study were man-
ufactured under specific conditions in order to be applicable
for bioavailability testing and for different therapeutic uses.
The Exo-d-MAPPS sample was engineered as a sterile prod-
uct and manufactured under current Good Manufacturing
Practices (cGMP) regulated and reviewed by the FDA. The
sterile Exo-d-MAPPS sample incorporates the Regenerative
Processing Plant’s (RPP) proprietary patented sterilization
process to provide a safe sterile product [25]. Briefly, PL-
MSCs were grown in complete MSC Dulbecco’s Modified
Eagle’s Medium (DMEM). Low passage (<5) PL-MSCs were
grown to 60%–80% confluence in multiflasks before isola-
tion. Fresh PL-MSC media were layered and collected after
48 to 72h (conditioned medium). Exos were isolated by the
ultracentrifugation protocol (100,000g at 4°C for 70min).
The isolation of Exos was performed by positive selection
using the μMACS™ Separator (Miltenyi Biotec, Bergisch
Gladbach, Germany; Cat. No. 130-042-602) and the Exo-
some Isolation Kit Pan, human (Miltenyi Biotec, Bergisch
Gladbach, Germany; Cat. No. 130-110-912) which contained
a cocktail of MicroBeads conjugated to the tetraspanin
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proteins CD9, CD63, and CD81. Briefly, Exos were magnet-
ically labeled and loaded onto a μ column, which was placed
in the magnetic field of a μMACS™ Separator. The magneti-
cally labeled Exos were retained within the column, while the
unlabeled vesicles and cell components run through the col-
umn. After removing the column from the magnetic field, the
intact Exos were collected by elution. Exos were stored at
−70°C until use [25].
2.2. Animals. For animal studies, eight- to ten-week-old male
BALB/c mice were used. Mice were maintained in animal
facilities of the Faculty of Medical Sciences, University of
Kragujevac, Serbia. All animals received humane care, and
all experiments were approved by and conducted in accor-
dance with the Guidelines of the Animal Ethics Committee
of the Faculty of Medical Sciences of the University of
Kragujevac. Mice were housed in a temperature-controlled
environment with a 12-hour light-dark cycle and were
administered with standard laboratory chow and water ad
libitum.
2.3. Animal Study Protocol. Animals were randomly divided
into control and experimental groups (n = 8mice per group).
Mice from the experimental group underwent whole-body
exposure to CS of 5 cigarettes in a CS chamber with 30-
minute smoke-free intervals, every day for four weeks
[26, 27]. The smoke exposure experimental box, adapted
for a group of 8 mice, consisted of a box body and a
cover. CS was drawn through an exposure chamber by
negative pressure using an extraction pump. Between
draws of CS, room air was continuously drawn through
the chamber. The smoke-to-air ratio was 1 : 12 to protect
mice from acute smoke toxicity and death.
After four weeks of CS treatment, mice were randomly
divided into two groups and received either vehicle or
Exo-d-MAPPS (0.1mL/intraperitoneally/5 days per week
for three weeks).
Mice from the control groups were exposed to air only
and received either vehicle or Exo-d-MAPPS.
2.4. Histopathological Analysis. All mice were sacrificed 8
weeks after initial CS exposure, and the lungs were isolated
for histopathological analysis. The isolated lungs were fixed
in 10% formalin, embedded in paraffin, and consecutive
4μm tissue sections were mounted on slides. Sections were
stained with hematoxylin and eosin (H&E) and examined
under a low-power (100x) light microscope-equipped digital
camera (Zeiss Axioskop 40, Jena, Germany) [28].
2.5. Blood Gas Analysis. In order to explore whether Exo-d-
MAPPS treatment managed to improve extracellular acid-
base status and gas exchange in CS-exposed mice, blood gas
parameters (partial pressure of oxygen in arterial blood
(PaO2), partial pressure of carbon dioxide (PaCO2) in arterial
blood, oxygen saturation (SaO2), and pH) were analyzed. For
this purpose, arterial blood samples were obtained from
control and experimental animals and analyzed within a
few minutes using a test cartridge blood analysis system
(Premier GEM 3500, Instrumentation Laboratory, Bedford,
Massachusetts, USA) [29].
2.6. Isolation of Lung-Infiltrated Immune Cells. The lungs,
obtained from control and CS-exposed mice, were washed
with sterile phosphate-buffered saline (PBS) and placed in
Petri dishes with DMEM supplemented with 10% FBS. The
dissected lung tissues were incubated in a medium that con-
tained collagenase type IV (0.5mg/mL) and type IV bovine
pancreatic DNAse (Roche Diagnostics; 1mg/mL) at 37°C
for 45min. The cells were filtered through a 100μm nylon
cell strainer into a clean 50mL conical tube. Then, cells were
pelleted by centrifuging for 10min at 300× g at 10°C. Red
blood cells were depleted with a lysis buffer (0.144M NH4Cl,
0.0169M TRIS base, pH7.4) at 37°C in a 5% CO2 atmosphere
for 5min [28].
2.7. Flow Cytometry Analysis and Intracellular Staining of
Lung-Infiltrated Immune Cells. Lung-infiltrated immune
cells were screened for various cell surface and intracellular
markers by flow cytometry. Since a combination of mechan-
ical and enzymatic dissociations of lung tissue may result in
cell damage and death, the MACS® Dead Cell Removal Kit
(Miltenyi Biotec, Bergisch Gladbach, Germany; Cat. No.
130-090-101) was used for magnetic cell separation of viable
cells. Briefly, a single-cell suspension of lung-infiltrated cells
was resuspended in 100μL of the Dead Cell Removal
MicroBeads (per 107 of cells), mixed, and incubated for
15min at room temperature. Cells were applied on MS col-
umns within 1 ×MACSBinding Buffer. Effluent that passed
through the column contained live cells. To reduce nonspe-
cific binding of antibodies, viable lung-infiltrated cells were
incubated with an anti-Fc block (anti-mouse CD16/CD32).
For that purpose, the cell suspension was incubated with
1μg of the BD Fc Block/106 cells in 100μL of staining buffer
(Dulbecco’s PBS (DPBS) without Mg2+ or Ca2+, 1% heat-
inactivated FCS, and 0.09% (w/v) sodium azide) for 15
minutes at 4°C. The cells were then washed and stained with
fluorochrome-conjugated antibodies. Briefly, 1 × 106 cells
were incubated with anti-mouse CD45, F4/80, I-A, CD80,
CD206, CD11c, NKp46, Gr-1, CD3, CD4, CD8, CXCR3,
monoclonal antibodies conjugated with fluorescein isothio-
cyanate (FITC), phycoerythrin (PE), peridinin chlorophyll
protein (PerCP), or allophycocyanin (APC) (all from BD
Biosciences, San Jose, CA, USA) in a staining buffer for
30min in the dark at 4°C. Cells were washed twice in a stain-
ing buffer and pelleted by centrifugation. For intracellular
cytokine staining, cells were stimulated with 50 ng/mL phor-
bol 12-myristate 13-acetate (PMA) and 500ng/mL ionomy-
cin for 5 h and GolgiStop (BD Biosciences, San Jose, CA,
USA; Cat. No. 554715) was added. Cells were then incubated
in a BD fixation/permeabilization solution (BD Cytofix/Cy-
toperm™ Fixation/Permeabilization Kit; Cat. No. 554714)
for 20min at 4°C. Afterwards, cells were washed two times
in 1×BD Perm/Wash™ buffer (BD Cytofix/Cytoperm™ Fix-
ation/Permeabilization Kit; Cat. No. 554714) and pelleted.
Fixed/permeabilized cells were concomitantly resuspended
in 50μL of BD Perm/Wash™ buffer containing a predeter-
mined optimal concentration of fluorochrome-conjugated
antibodies specific for FoxP3, TNF-α, IL-12, IL-10, IL-1β,
IFN-γ, and IL-17 by using appropriate anti-mouse monoclo-
nal antibodies conjugated with FITC, PE, PerCP, and APC
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(BD Biosciences, San Jose, CA, USA). Cells were incubated
with fluorochrome-conjugated antibodies at 4°C for 30
minutes in the dark. Afterwards, cells were washed 2 times
with 1×BD Perm/Wash™ buffer and resuspended in a stain-
ing buffer prior to flow cytometric analysis. In experiments in
which the phenotype and function of T cells were analyzed,
CD3+ T lymphocytes were isolated from the population of
viable lung-infiltrated cells by magnetic separation. For that
purpose, the MACS Separator, the MACS Columns, and
the CD3ε MicroBead Kit, mouse (Miltenyi Biotec, Bergisch
Gladbach, Germany; Cat. No. 130-094-973) were used.
Afterwards, CD3+ T cells were stained with fluorochrome-
conjugated anti-mouse antibodies specific for CD4, CD8,
CXCR3, FoxP3, TNF-α, IL-10, IFN-γ, and IL-17, following
the procedure that was described above. Flow cytometric
analysis was conducted on a BD Biosciences’ FACSCalibur
and analyzed by using the Flowing Software analysis pro-
gram [28].
2.8. Determination of Cytokines in Serum Samples of Control
and Experimental Animals. The commercial ELISA sets
(R&D Systems, Minneapolis, MN, USA) were used to
determine the concentration of TNF-α, IL-12, IL-10,
IL-1β, and IFN-γ in serum samples of control and
experimental animals [28].
2.9. Patients. Thirty COPD patients were recruited with the
aim to receive an Exo-d-MAPPS inhalation solution.
Patients enrolled in this study were men (n = 20) or post-
menopausal women (n = 10) aged between 50 and 75
years, having a postbronchodilator forced expiratory
volume in 1 s ðFEV1Þ ≥ 30% and <80% predicted, a post-
bronchodilator FEV1/forced vital capacity ðFVCÞ < 70%, a
smoking history of ≥10 pack-year, and lung hyperinflation
defined as a functional residual capacity (FRC) greater than
120%. Subjects with past or current history of abnormal vital
signs, abnormal laboratory findings, clinically relevant ECG
abnormalities, or cardiovascular conditions prior to screen-
ing were excluded from the study. All subjects provided writ-
ten informed consent prior to study participation.
2.10. Clinical Study Protocol. Patients received Exo-d-
MAPPS inhalation solution (0.5mL/once per week for three
weeks) containing a high concentration of immunosuppres-
sive factors (soluble TNF receptors I and II (sTNFRI and
sTNFRII), IL-1 receptor antagonist (IL-1Ra), and soluble
receptor for advanced glycation end products (sRAGE))
[25, 30]. Pulmonary function tests and clinical findings were
recorded before and 1 month after Exo-d-MAPPS treatment.
Spirometry was performed according to recommendations
from the American Thoracic Society guidelines [31, 32].
Forced expiratory volume in 1 second (FEV1) and peak expi-
ratory flow (PEF) rate were recorded. Chest computed
tomography (CT), standard clinical COPD questionnaire
(CCQ) scoring, and 6-minute walking distance (6MWD) test
as a submaximal test of aerobic capacity/endurance were
used to determine the effects of Exo-d-MAPPS treatment,
as previously described [33–35].
2.11. Statistical Analysis. The results obtained in the animal
study were analyzed using the Student t-test. All data in ani-
mal studies were expressed as the mean ± standard error of
themean (SEM). The Wilcoxon signed-rank test was applied
to demonstrate differences in pulmonary function of COPD
patients before and after Exo-d-MAPPS treatment. Values
of P < 0:05 were considered as statistically significant.
3. Results
3.1. Exo-d-MAPPS Attenuated Chronic Airway Inflammation
in Mice. The analysis of arterial blood gas parameters, includ-
ing PaO2, PaCO2, pH, and SaO2 (Figures 1(a)–1(d)), indi-
cated respiratory dysfunction in CS-exposed mice which
was manifested by tiredness, fatigue, and reduced activity.
Importantly, remarkably improved respiratory function, as
evidenced by significantly elevated PaO2 (Figure 1(a),
P < 0:0001), O2 saturation (Figure 1(c), P < 0:0001), and
pH (Figure 1(d), P < 0:0001) and decreased PaCO2
(Figure 1(b), P < 0:0001) was observed in CS-treated mice
that received Exo-d-MAPPS. Accordingly, depression-like
behavior and loss of locomotor activity were not seen in
CS+Exo-d-MAPPS-treated animals.
The alveolar wall was intact, and leucocyte accumulation
was not seen in the lung parenchyma of control animals
(Figures 1(e), A and 1(e), B). On the contrary, partial alveolar
wall destruction, widened alveolar septa and expanded alveo-
lar space, capillary dilation, and congestion with massive
infiltration of neutrophils, lymphocytes, and monocytes were
observed in the lungs of CS-exposed mice (Figure 1(e), C;
black arrows). Importantly, preserved alveolar and blood ves-
sel structures and a significantly lower number of lung-
infiltrated leucocytes were noticed in the lungs of CS+Exo-
d-MAPPS-treated animals (Figures 1(e) D) indicating that
Exo-d-MAPPS managed to attenuate inflammation-related
pathological changes in the lungs of CS-exposed mice.
In line with these findings, a significantly lower concen-
tration of inflammatory cytokines that play an important
pathogenic role in the development and progression of CS-
induced airway inflammation (TNF-α, IL-1β, IL-12, and
IFN-γ) was observed in serum samples of Exo-d-MAPPS-
treated CS-exposed mice compared to CS+vehicle-treated
animals (Figure 1(f); P < 0:05 for TNF-α, IL-12, and IFN-γ;
P < 0:01 for IL-1β). Additionally, Exo-d-MAPPS treatment
resulted in the elevation of anti-inflammatory and immuno-
suppressive IL-10 (Figure 1(g), P < 0:01) which is involved in
lung repair and regeneration [4].
3.2. Exo-d-MAPPS Significantly Attenuated Influx of
Inflammatory Macrophages, Neutrophils, and NK and NKT
Cells in Inflamed Lungs. Macrophages have a crucially
important role in the development and progression of
CS-induced airway inflammation in mice, and their number
corresponds to the extent of lung injury and inflammation
[36]. Exo-d-MAPPS treatment managed to significantly
reduce the total number of lung-infiltrated macrophages in
CS-exposed mice (Figure 2(b), P < 0:001). Additionally,
Exo-d-MAPPS remarkably attenuated antigen-presenting
capacities of alveolar macrophages as evidenced by a
4 Analytical Cellular Pathology
0
20
40
60
80
100
120
⁎⁎⁎
PaO2
m
m
H
g
Vehicle treated
Exo-d-MAPPS treated
CS+vehicle treated 
CS+Exo-d-MAPPS treated
(a)
0
10
20
30
40
50
60
70
80
90
100
PaCO2
m
m
H
g
⁎⁎⁎
Vehicle treated
Exo-d-MAPPS treated
CS+vehicle treated 
CS+Exo-d-MAPPS treated
(b)
0
20
40
60
80
100
120
SaO2
%
⁎⁎⁎
Vehicle treated
Exo-d-MAPPS treated
CS+vehicle treated 
CS+Exo-d-MAPPS treated
(c)
6.5
6.6
6.7
6.8
6.9
7
7.1
7.2
7.3
7.4
7.5
pH
⁎⁎⁎
Vehicle treated
Exo-d-MAPPS treated
CS+vehicle treated 
CS+Exo-d-MAPPS treated
(d)
Vehicle treated
Exo-d-MAPPS treated
CS+vehicle treated
CS+Exo-d-MAPPS treated
(A)
(B)
(C)
(D)
(e)
Figure 1: Continued.
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significantly reduced number of CD80- and I-A-expressing
F4/80+ cells in the lungs of CS+Exo-d-MAPPS-treated ani-
mals (Figures 2(c) and 2(d), P < 0:001). Intracellular staining
revealed that Exo-d-MAPPS significantly attenuated the pro-
duction of inflammatory TNF-α (Figure 2(e), P < 0:001) and
IL-12 (Figure 2(f), P < 0:01) in lung-infiltrated macrophages.
Furthermore, a significantly higher number of alternatively
activated, IL-10-producing and CD206-expressing M2 mac-
rophages were noticed in the lungs of Exo-d-MAPPS-treated
CS-exposed mice (Figures 2(g) and 2(h), P < 0:01), indicating
that Exo-d-MAPPS treatment suppressed inflammation and
promoted the generation of an immunosuppressive pheno-
type in lung-infiltrated macrophages.
Additionally, Exo-d-MAPPS attenuated the capacity of
NK and NKT cells and neutrophils to produce inflamma-
tory cytokines in CS-injured lungs. A significantly lower
number of IL-17A-producing NK and NKT cells
(Figures 3(b) and 3(c), P < 0:001 for NK and P < 0:05 for
NKT cells), IFN-γ-secreting NK and NKT cells
(Figures 3(d) and 3(e), P < 0:001), and TNF-α and IL-1β-
producing neutrophils (Figures 3(g) and 3(h), P < 0:001)
were observed in the lungs of Exo-d-MAPPS-treated CS-
exposed mice.
3.3. Exo-d-MAPPS Significantly Alleviated Antigen-
Presenting Properties of Lung-Infiltrated DCs That Resulted
in Attenuated Activation of CD4+ and CD8+ T
Lymphocytes. Airway DCs initiate and orchestrate T cell-
driven inflammation in CS-injured lungs [34]. Lung DCs
form a sentinel network around the airways, capture antigens
that pass through the injured epithelium, and become acti-
vated. Activated DCs migrate to the draining lymph nodes
to convey antigenic information to specialized T lympho-
cytes, inducing the generation of effector CD4+ T helper cells
and CD8+CTLs [37, 38]. As it is shown in Figure 4, Exo-
d-MAPPS affected the migratory and antigen-presenting
properties of DCs. A significantly lower number of
F4/80-CD11c+I-A+ DCs were observed in the CS-injured
lungs of Exo-d-MAPPS-treated animals (Figure 4(b), P <
0:001). The total number of lung-infiltrated F4/80-CD11c+I-
A+ DCs that express costimulatory molecule CD80
(Figure 4(c), P < 0:01) was significantly lower in CS-treated
mice that received Exo-d-MAPPS. Furthermore, a decreased
number of proinflammatory, IL-12-producing F4/80-CD11c
+I-A+ DCs (Figure 4(d), P < 0:001) and an increased presence
of immunosuppressive and tolerogenic, IL-10-producing
F4/80-CD11c+I-A+ DCs (Figure 4(e), P < 0:001) were
observed in the lungs of CS+Exo-d-MAPPS-treated animals,
indicating that Exo-d-MAPPS attenuated the antigen-
presenting and proinflammatory properties of airway DCs.
Exo-d-MAPPS-induced modulation of DC function
resulted in alleviated activation of inflammatory, IFN-γ-
and IL-17-producing CD4+ and CD8+ T lymphocytes
(Figures 5(b)–5(e)). A significantly lower number of
CXCR3-expressing and IFN-γ-producing CD4+Th1 cells
(Figure 5(b), P < 0:01) and IL-17-producing CD4+Th17 cells
(Figure 5(c), P < 0:01) were observed in the lungs of Exo-d-
MAPPS-treated CS-exposed mice. Similarly, Exo-d-MAPPS
treatment attenuated the influx of CXCR-expressing, IFN-
γ-producing (Figure 5(d), P < 0:001), and IL-17-producing
CD8+CTLs (Figure 5(e), P < 0:01) and reduced the total
number of alveolotoxic, TNF-α-producing CD8+CTLs
(Figure 5(f), P < 0:001) in CS-injured lungs. Importantly,
Exo-d-MAPPS significantly increased the total number of
lung-infiltrated anti-inflammatory, IL-10-producing CD4
+FoxP3+T regulatory cells (Tregs) (Figure 5(g), P < 0:05),
enabling the generation of an immunosuppressive microen-
vironment in the inflamed lungs.
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Figure 1: Exo-d-MAPPS attenuated CS-induced airway inflammation in mice. Exo-d-MAPPS significantly improved pulmonary function in
CS-exposed mice, as evidenced by blood gas analysis: significantly elevated PaO2, SaO2, and pH and decreased PaCO2 (a–d). Representative
H&E staining of the lungs (×100 magnification) obtained from the control ((e) A and (e) B) and experimental mice ((e) C and (e) D) showing
partial alveolar wall destruction, widened alveolar septa and expanded alveolar space, and capillary dilation and congestion with massive
infiltration of neutrophils, lymphocytes, and monocytes in the lungs of CS-exposed mice (e-C; black arrows) and alveolar and blood
vessel structures with a lower number of lung-infiltrated leucocytes in the lungs of CS+Exo-d-MAPPS-treated animals (e-D).
Significantly downregulated levels of proinflammatory cytokines (TNF-α, IL-12, IFN-γ, and IL-1β) (f) and increased concentration of
anti-inflammatory IL-10 (g) in serum samples of CS+Exo-d-MAPPS-treated animals. Values are presented as mean ± SEM; n = 8
mice/group. ∗P < 0:05, ∗∗P < 0:01, and ∗∗∗P < 0:001.
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3.4. Exo-d-MAPPS Treatment Significantly Improved
Pulmonary Status of COPD Patients. In order to investigate
the relevance of the experimental findings for correspond-
ing human pathology, we evaluated the efficacy of the
Exo-d-MAPPS inhalation solution for the attenuation of
airway inflammation in patients suffering from COPD
(Figure 6). As it is shown in Figure 6(a), Exo-d-MAPPS
contained a high concentration of soluble immunosup-
pressive mediators (sTNFRI, sTNFRII, IL-1Ra, and
sRAGE). Clinical parameters (Figures 6(b)–6(e)) and CT
findings (Figure 6(f)) indicated the beneficial effects of
Exo-d-MAPPS in the alleviation of chronic lung inflamma-
tion. All of the 30 Exo-d-MAPPS-treated patients showed a
marked improvement in pulmonary status, as evidenced by
an increase in percentage change relative to the initial value
of FEV1 (%ΔFEV1), significantly higher PEF, decreased
CCQ total score, and increased 6-minute walking distance
(6MWD) (Figures 6(b)–6(e)). Additionally, quality of life
was significantly improved after Exo-d-MAPPS treatment
and all Exo-d-MAPPS-treated patients managed to perform
daily activities without hindrance. Clinical findings were con-
firmed by CT. Inflammation-induced destruction of alveoli
and air trapping caused hyperinflation of the lungs with flat-
tening of the diaphragm in COPD patients (Figure 6(f), red
arrows). Exo-d-MAPPS significantly alleviated emphysema-
tous changes in the lungs of COPD patients. Lungs were less
hyperexpanded, diaphragms were less flattened, and cen-
trilobular and paraseptal emphysema were significantly
reduced one month after Exo-d-MAPPS administration
(Figure 6(g), green arrows), indicating the beneficial effects
of Exo-d-MAPPS in the attenuation of emphysema in
COPD patients. Importantly, Exo-d-MAPPS was well tol-
erated. None of the 30 Exo-d-MAPPS-treated COPD
patients reported any side effects related to Exo-d-
MAPPS administration.
4. Discussion
MSCs are considered new therapeutic agents in the cell-based
therapy of chronic inflammatory lung disorders due to their
capacity to suppress detrimental immune response in the
lungs and due to their ability to differentiate into alveolar
cells, lung epithelial cells, and vascular and endothelial cells
[39]. Nevertheless, results obtained in several animal models
suggested that transplanted MSCs, in response to the growth
factors produced in the local microenvironment, may also
differentiate into undesired tissues, mainly bone and cartilage
[40, 41]. Although MSCs have a low expression of major his-
tocompatibility class (MHC) molecules, several lines of evi-
dence indicated that transplantation of allogeneic MSCs can
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induce allogeneic immune responses in MHC-mismatched
recipients [42–45]. Therefore, the safety issue related to
MSC-based therapy is still a matter of debate [46].
Since most of the MSC-mediated beneficent effects in the
attenuation of inflammatory lung diseases were a conse-
quence of their paracrine action [36] and in order to avoid
safety concerns related to unwanted differentiation of trans-
planted MSCs or their allogeneic rejection [40–45], we
designed Exo-d-MAPPS, a PL-MSC-derived soluble product,
which contains MSC-derived Exos with immunomodulatory
factors involved in lung repair and regeneration (sTNFRI,
sTNFRII, IL-1Ra, and sRAGE).
By using clinical data and a complementary animal
model, herewith, we demonstrated the therapeutic potential
of Exo-d-MAPPS in the alleviation of chronic airway inflam-
mation. A marked improvement in pulmonary function and
significantly attenuated airway inflammation were observed
in COPD patients one month after Exo-d-MAPPS treatment.
Similarly, a preserved alveolar structure and a diminished
number of lung-infiltrated leucocytes were noticed in the
lungs of CS+Exo-d-MAPPS-treated mice indicating that
Exo-d-MAPPS efficiently alleviated inflammation-related
pathological changes in the CS-injured lungs.
The beneficial effects of Exo-d-MAPPS in the alleviation
of CS-induced COPD relied on the suppression of inflamma-
tory immune cells in the lungs, and therefore, Exo-d-MAPPS
was administered as an inhalation solution in COPD
patients. Mice appear to lack respiratory bronchioles, par-
tially alveolarized conducting airways, which are the sites of
CS-induced emphysema [47]. Despite the species-specific
difference in airway anatomy between mice and humans,
mice have been the most usually used animal models for
the investigation of the molecular and cellular mechanisms
responsible for the therapeutic effects of newly developed
drugs in COPD [48]. Among all routes for the daily applica-
tion of the drugs, intraperitoneal administration is the most
commonly used in mice since it is simple to perform and it
results in a fast absorption of the drug into the vasculature
[49]. On the contrary, during inhalational drug administra-
tion, mice should be conditioned to restraint devices and
nose masks [49]. Stress, associated with physical restraint,
has been shown to cause a negative impact on the
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cardiovascular and immune systems of mice and, accord-
ingly, may alter the therapeutic effects of immunosuppressive
agents, including Exo-d-MAPPS [50]. For these reasons,
Exo-d-MAPPS was administered intraperitoneally in mice
and by inhalation in COPD patients.
Alveolar epithelial cells exposed to CS produce TNF-α
and IL-1β which bind to their receptors on lung endothelial
cells (ECs) and induce increased expression of selectins and
integrin ligands enabling massive accumulation of circulating
leucocytes in the inflamed lungs [51]. Accordingly, TNF-α
and IL-1β are considered inflammatory cytokines with the
most important pathogenic role in the initial phase of lung
injury and inflammation [51, 52]. Soluble TNF receptors
(sTNFRI and sTNFRII) suppress TNF-α-driven chronic air-
way inflammation, and their serum and sputum levels posi-
tively correlate with lung function in COPD patients;
therefore, sTNFRI and sTNFRII are considered important
anti-inflammatory mediators responsible for lung repair
and regeneration [53]. Similarly, MSC-derived IL-1Ra, a nat-
urally occurring cytokine, acts as a competitive inhibitor of
IL-1β and attenuates lung injury by preventing IL-1β-depen-
dent accumulation of inflammatory cells in injured lungs
[54]. IL-1Ra binds to IL-1R on ECs and prevents proinflam-
matory events initiated by an IL-1β : IL-1R interaction,
including enhanced influx of neutrophils, macrophages,
and lymphocytes in inflamed lungs [54]. In line with these
findings, we assume that sTNFRI, sTNFRII, and IL-1Ra,
which were present in high concentration in the Exo-d-
MAPPS sample, were responsible for downregulated serum
levels of TNF-α and IL-1β and for the significantly reduced
presence of inflammatory TNF-α-producing macrophages
and TNF-α- and IL-1β-producing neutrophils in the lungs
of CS+Exo-d-MAPPS-treated animals.
NK and NKT cells promote lung injury and inflamma-
tion either directly, by inducing apoptosis of alveolar
epithelial cells, or indirectly, through the secretion of
inflammatory cytokines (IL-17A and IFN-γ), which regu-
late the accumulation and activation of inflammatory mac-
rophages in the CS-injured lungs [55]. Accordingly, the
attenuated injury of alveolar epithelial cells, noticed in
the lungs of Exo-d-MAPPS-treated CS-exposed mice, was
accompanied by the remarkably reduced presence of IL-
17A- and IFN-γ-producing lung-infiltrated NK and NKT
cells and significantly lower number of inflammatory M1
macrophages.
Exposure of alveolar epithelial cells to inflammatory
cytokines results in the generation of oxidative stress which
leads to the accelerated formation and accumulation of
advanced glycation end products (AGEs). AGEs bind to their
receptors (RAGEs) and cause lung injury through the forma-
tion of crosslinks within protein molecules [56]. Accordingly,
the increased expression of AGEs and RAGEs was observed
in the lungs of COPD patients, suggesting their important
pathogenic role in the development and progression of
chronic airway inflammation [57]. On the contrary, sRAGE
acts as a decoy receptor which removes circulating AGEs,
prevents their ligation to membrane bound RAGEs, and pro-
tects lung tissue from injury [58, 59]. Additionally, sRAGE
suppresses AGE :RAGE-dependent production of inflamma-
tory cytokines in mononuclear cells and promotes the gener-
ation of alternatively activated macrophages and regulatory
DCs [60]. These anti-inflammatory cells have a reduced
expression of MHC class II proteins and costimulatory
molecules, induce the anergy of effector T cells, and pro-
mote the generation and expansion of immunosuppressive
Tregs [61, 62]. In line with these findings, we assume that
sRAGE, which was found in high concentration in Exo-d-
MAPPS samples, was responsible for the reduced number
of CD80 and I-A-expressing macrophages and DCs and
for the increased presence of immunosuppressive, IL-10-
producing alternatively activated M2 macrophages, regula-
tory DCs, and Tregs in the lungs of CS+Exo-d-MAPPS-
treated mice.
IL-10-producing cells created an immunosuppressive
microenvironment in the lungs of CS+Exo-d-MAPPS-
treated animals and suppressed detrimental TNF-α, IFN-γ,
and IL-17-driven T cell immune response. It is well known
that TNF-α-, IFN-γ-, and IL-17-producing CD8+CTLs and
CD4+ T helper cells have an important pathogenic role in
the development and progression of COPD [61]. Lung-
infiltrated CD8+CTLs induce the cell death of alveolar epi-
thelial cells either directly, through the secretion of cytotoxic
molecules (TNF-α, perforins, and granzymes), or indirectly,
through the production of IFN-γ or IL-17 which promotes
tissue destruction by promoting the secretion of matrix
metalloproteinases (MMPs), TNF-α, and IL-1β in macro-
phages and neutrophils [63, 64]. In a similar manner, IFN-
γ- or IL-17-producing CD4+Th1 and Th17 cells orchestrate
immune response in inflamed lungs by amplifying the activa-
tion of lung-infiltrated inflammatory macrophages and neu-
trophils [61, 63]. Additionally, CD4+ T cells promote long-
term survival of CD8+CTLs and are essential for the full
development of CTL-mediated cytotoxicity in inflamed lungs
[61, 63]. Accordingly, we believe that the Exo-d-MAPPS-
induced expansion of lung-infiltrated IL-10-producing mac-
rophages, DCs, and Tregs and elevated serum levels of IL-10
were responsible for attenuated T cell-driven airway inflam-
mation and reduced injury of alveolar epithelial cells which
were observed in CS+Exo-d-MAPPS-treated animals,
5. Conclusions
In summary, we propose that the main mechanism of
action responsible for Exo-d-MAPPS-based alleviation of
COPD relied on anti-inflammatory effects of soluble medi-
ators (sTNFRI and II, IL-1Ra, and sRAGE) which inhib-
ited the influx of inflammatory leukocytes and promoted
the expansion of immunosuppressive cells in the lungs.
Alteration in the cellular makeup of the lungs resulted in
the creation of an anti-inflammatory microenvironment
which enabled enhanced tissue repair and regeneration
and improved pulmonary function of CS-exposed animals
and COPD patients. Therefore, we believe that Exo-d-
MAPPS could be considered a potentially new therapeutic
agent in the treatment of chronic inflammatory lung dis-
eases whose efficacy should be further explored in large
clinical trials.
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